JP5476544B2 - ノロウイルスワクチン製剤 - Google Patents

ノロウイルスワクチン製剤 Download PDF

Info

Publication number
JP5476544B2
JP5476544B2 JP2009530639A JP2009530639A JP5476544B2 JP 5476544 B2 JP5476544 B2 JP 5476544B2 JP 2009530639 A JP2009530639 A JP 2009530639A JP 2009530639 A JP2009530639 A JP 2009530639A JP 5476544 B2 JP5476544 B2 JP 5476544B2
Authority
JP
Japan
Prior art keywords
composition
formulation
dry powder
norovirus
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009530639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505766A (ja
Inventor
リチャードソン，チャールズ
ヴェドヴィック，トーマス，エス．
フォーベルト，トーマス，アール．
ティノ，ウィリアム，ティー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5476544(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of JP2010505766A publication Critical patent/JP2010505766A/ja
Application granted granted Critical
Publication of JP5476544B2 publication Critical patent/JP5476544B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2009530639A 2006-09-29 2007-09-28 ノロウイルスワクチン製剤 Active JP5476544B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84791206P 2006-09-29 2006-09-29
US60/847,912 2006-09-29
US97339207P 2007-09-18 2007-09-18
US60/973,392 2007-09-18
PCT/US2007/079929 WO2008042789A1 (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013131559A Division JP5898133B2 (ja) 2006-09-29 2013-06-24 ノロウイルスワクチン製剤

Publications (2)

Publication Number Publication Date
JP2010505766A JP2010505766A (ja) 2010-02-25
JP5476544B2 true JP5476544B2 (ja) 2014-04-23

Family

ID=39268804

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009530639A Active JP5476544B2 (ja) 2006-09-29 2007-09-28 ノロウイルスワクチン製剤
JP2013131559A Active JP5898133B2 (ja) 2006-09-29 2013-06-24 ノロウイルスワクチン製剤
JP2015197633A Active JP6134364B2 (ja) 2006-09-29 2015-10-05 ノロウイルスワクチン製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013131559A Active JP5898133B2 (ja) 2006-09-29 2013-06-24 ノロウイルスワクチン製剤
JP2015197633A Active JP6134364B2 (ja) 2006-09-29 2015-10-05 ノロウイルスワクチン製剤

Country Status (16)

Country Link
US (8) US7955603B2 (cg-RX-API-DMAC10.html)
EP (4) EP2601969B1 (cg-RX-API-DMAC10.html)
JP (3) JP5476544B2 (cg-RX-API-DMAC10.html)
KR (1) KR101515489B1 (cg-RX-API-DMAC10.html)
AU (1) AU2007303608B2 (cg-RX-API-DMAC10.html)
CA (1) CA2664157C (cg-RX-API-DMAC10.html)
CY (1) CY1118492T1 (cg-RX-API-DMAC10.html)
DK (3) DK2601970T3 (cg-RX-API-DMAC10.html)
ES (3) ES2618885T3 (cg-RX-API-DMAC10.html)
HU (2) HUE032422T2 (cg-RX-API-DMAC10.html)
LT (1) LT2601970T (cg-RX-API-DMAC10.html)
PL (2) PL2601970T3 (cg-RX-API-DMAC10.html)
PT (1) PT2601970T (cg-RX-API-DMAC10.html)
SG (3) SG10202012986SA (cg-RX-API-DMAC10.html)
SI (1) SI2601970T1 (cg-RX-API-DMAC10.html)
WO (1) WO2008042789A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013234188A (ja) * 2006-09-29 2013-11-21 Takeda Vaccines (Montana) Inc ノロウイルスワクチン製剤
US9801934B2 (en) 2011-07-11 2017-10-31 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
US9821049B2 (en) 2007-09-18 2017-11-21 Takeda Vaccines, Inc. Method of conferring a protective immune response to Norovirus
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2683977C (en) * 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
JP5852883B2 (ja) * 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
WO2010111586A2 (en) * 2009-03-27 2010-09-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Mucosal immunization
US20110070260A1 (en) * 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
JP2013517773A (ja) * 2010-01-21 2013-05-20 リゴサイト ファーマスーティカルズ，インコーポレイテッド カリシウイルスウイルス様粒子上の標的化異種抗原提示
AU2012244077B2 (en) * 2010-04-15 2015-06-18 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery
EP2689785B1 (en) * 2010-04-15 2021-05-19 Shin Nippon Biomedical Laboratories, Ltd. Method for generating dry vaccine powder formulation for inranasal delivery
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US20140017257A1 (en) * 2012-07-11 2014-01-16 Xi Jiang IgY From Norovirus P Particles And Their Derivatives
ES2677723T3 (es) * 2012-12-28 2018-08-06 Cellestis Limited Un ensayo de la respuesta inmunológica mediada por células
EP2970395A4 (en) * 2013-03-15 2017-03-29 The University of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
JP2015017065A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
CN105358178B (zh) 2013-07-17 2019-05-31 陶氏环球技术有限责任公司 用于施加到粘膜的包含甲基纤维素的组合物
JP2016533172A (ja) 2013-10-03 2016-10-27 タケダ ワクチン，インコーポレイテッド 細胞株からラブドウイルスを検出および除去する方法
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
AU2016317661B2 (en) 2015-08-28 2023-05-18 Ology Bioservices, Inc. Norovirus vaccine
KR101915740B1 (ko) * 2016-03-18 2018-11-06 (주)인테라 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
WO2019104439A1 (en) 2017-11-30 2019-06-06 Medicago Inc. Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
JP2021514391A (ja) 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
JP6713013B2 (ja) * 2018-03-06 2020-06-24 株式会社イーダブルニュートリション・ジャパン 貝類のノロウイルス不活化方法
EP3821014A4 (en) 2018-07-13 2022-04-20 Medicago Inc. MODIFIED NOROVIRUS VP1 PROTEINS AND VLPS WITH MODIFIED NOROVIRUS VP1 PROTEINS
JP2021534074A (ja) 2018-08-20 2021-12-09 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Ｖｌｐ製剤
EP3852820B1 (en) * 2018-09-17 2024-11-20 Board of Regents, The University of Texas System Compositions and methods for treating bone injury
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
US20220152186A1 (en) 2019-03-12 2022-05-19 Icon Genetics Gmbh Norovirus-like particles with improved stability
EP4021409A2 (en) * 2019-08-13 2022-07-06 Altimmune Inc Therapeutic agent effectiveness and its route of administration
US20240288407A1 (en) * 2020-06-15 2024-08-29 CureVac SE Analysis of nucleic acid mixtures
WO2022246323A1 (en) 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN115677838A (zh) * 2021-07-29 2023-02-03 成都康华生物制品股份有限公司 六价诺如病毒VLPs疫苗及其制备方法
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) * 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
AU683211B2 (en) 1992-04-08 1997-11-06 United States of America as represented by The Secretary Department of Health and Human Services, The Wild-type measles virus glycoproteins: vaccine and detection method therefor
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
ES2264126T3 (es) 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
US5645051A (en) * 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) * 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
WO1998044944A2 (en) 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
EP1105466B1 (en) 1998-08-14 2006-04-26 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles
CA2354444A1 (en) 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
ATE413188T1 (de) 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
CA2375337C (en) 1999-06-22 2012-09-25 Naokazu Takeda Srsv detection kit
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
ATE489969T1 (de) 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
CA2514667C (en) 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
WO2004073652A2 (en) 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) * 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
JP2007537137A (ja) 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2006074303A2 (en) 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
ES2424229T3 (es) 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
CA2608515A1 (en) 2005-06-01 2007-05-10 Dow Global Technolgies Inc. Production of multivalent virus like particles
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
EP2601969B1 (en) * 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
US8474614B2 (en) * 2007-03-14 2013-07-02 BBY Solutions Protective container for a flat screen monitor
CN104740624B (zh) * 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CA2750321A1 (en) 2009-01-22 2010-07-29 Pharmathene, Inc. Stable vaccine compositions and methods of use
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
JP2013517773A (ja) 2010-01-21 2013-05-20 リゴサイト ファーマスーティカルズ，インコーポレイテッド カリシウイルスウイルス様粒子上の標的化異種抗原提示
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010599B2 (en) 2006-09-29 2018-07-03 Takeda Vaccines, Inc. Norovirus vaccine formulations
JP2016020378A (ja) * 2006-09-29 2016-02-04 タケダ ワクチン，インコーポレイテッド ノロウイルスワクチン製剤
US10512682B2 (en) 2006-09-29 2019-12-24 Takeda Vaccines, Inc. Norovirus vaccine formulations
JP2013234188A (ja) * 2006-09-29 2013-11-21 Takeda Vaccines (Montana) Inc ノロウイルスワクチン製剤
US9861691B2 (en) 2006-09-29 2018-01-09 Takeda Vaccines, Inc. Norovirus vaccine formulations
US9821049B2 (en) 2007-09-18 2017-11-21 Takeda Vaccines, Inc. Method of conferring a protective immune response to Norovirus
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
US10688174B2 (en) 2007-09-18 2020-06-23 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
US11040097B2 (en) 2007-09-18 2021-06-22 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
US11826415B2 (en) 2007-09-18 2023-11-28 Takeda Vaccines, Inc. Method of conferring a protective immune response to Norovirus
US9867876B2 (en) 2011-07-11 2018-01-16 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
US9801934B2 (en) 2011-07-11 2017-10-31 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
US10675341B2 (en) 2011-07-11 2020-06-09 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
US11701420B2 (en) 2011-07-11 2023-07-18 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations

Also Published As

Publication number Publication date
JP5898133B2 (ja) 2016-04-06
ES2420136T3 (es) 2013-08-22
SG174845A1 (en) 2011-10-28
SG10201502490YA (en) 2015-05-28
EP2066354B1 (en) 2013-04-17
US20120093861A1 (en) 2012-04-19
DK2601970T3 (en) 2017-02-06
JP2010505766A (ja) 2010-02-25
ES2618885T3 (es) 2017-06-22
PL2601970T3 (pl) 2017-07-31
EP2066354A4 (en) 2010-10-20
EP2601969A3 (en) 2013-08-21
US20080299152A1 (en) 2008-12-04
HUE028978T2 (en) 2017-02-28
US20120156243A1 (en) 2012-06-21
DK2066354T3 (da) 2013-05-27
PL2601969T3 (pl) 2016-10-31
EP2641613A1 (en) 2013-09-25
EP2601969B1 (en) 2016-03-30
EP2601970A1 (en) 2013-06-12
US20190125853A1 (en) 2019-05-02
US10512682B2 (en) 2019-12-24
US10010599B2 (en) 2018-07-03
US9861691B2 (en) 2018-01-09
AU2007303608A1 (en) 2008-04-10
US20160008455A1 (en) 2016-01-14
DK2601969T3 (en) 2016-04-18
CA2664157A1 (en) 2008-04-10
US20130273105A1 (en) 2013-10-17
SG10202012986SA (en) 2021-01-28
HK1184057A1 (en) 2014-01-17
PT2601970T (pt) 2017-02-02
US20140286994A1 (en) 2014-09-25
US8431116B2 (en) 2013-04-30
CY1118492T1 (el) 2017-07-12
US20130273148A1 (en) 2013-10-17
SI2601970T1 (sl) 2017-04-26
ES2577833T3 (es) 2016-07-19
HUE032422T2 (en) 2017-09-28
LT2601970T (lt) 2017-04-25
EP2066354A1 (en) 2009-06-10
WO2008042789A1 (en) 2008-04-10
JP2013234188A (ja) 2013-11-21
CA2664157C (en) 2015-12-01
US9308249B2 (en) 2016-04-12
AU2007303608B2 (en) 2013-05-02
KR101515489B1 (ko) 2015-04-30
JP6134364B2 (ja) 2017-05-24
US9272028B2 (en) 2016-03-01
EP2601970B1 (en) 2016-10-26
EP2601969A2 (en) 2013-06-12
JP2016020378A (ja) 2016-02-04
KR20090079912A (ko) 2009-07-22
US7955603B2 (en) 2011-06-07

Similar Documents

Publication Publication Date Title
JP6134364B2 (ja) ノロウイルスワクチン製剤
JP6296885B2 (ja) ノロウイルスに対して防御免疫応答を付与する方法
HK1184057B (en) Norovirus vaccine formulations
HK1189812A (en) Liquid norovirus vaccine formulations comprising toll-like receptor (tlr) agonist as adjuvant
HK1183794B (en) Norovirus vaccine formulations
HK1183794A (en) Norovirus vaccine formulations

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120918

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121016

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130624

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140114

R150 Certificate of patent or registration of utility model

Ref document number: 5476544

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250